Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction.

CONTEXT Preeclampsia (PE), a pregnancy-specific disorder closely associated with endothelial dysfunction and capillary leakage, is responsible for substantial maternal/fetal morbidity and mortality. PE can be classified as early-onset (<34 wk) and late-onset (>34 wk); the two subsets differ in presentation and pathogenesis. OBJECTIVES The objectives of the study were to examine serine protease high-temperature requirement factor A4 (HtrA4) expression in the placenta and other human tissues and in early-onset vs late-onset PE, to determine serum HtrA4 levels in normal pregnancy and in PE subtypes, and to investigate the effect of high levels of HtrA4 on endothelial integrity and function. METHODS Microarray data analysis and RT-PCR determined HtrA4 expression in the human placenta, various tissues, and cell lines. The serum HtrA4 protein levels were analyzed by an ELISA. The potential impact of excessive circulating HtrA4 on the maternal vasculature was determined by in vitro endothelial tube and permeability assays. RESULTS Human HtrA4 expression was restricted to the placenta and significantly up-regulated in early-onset but not late-onset PE. The serum HtrA4 levels in normal pregnancy increased significantly between the first and second trimesters and then remained constant. Women with early-onset but not late-onset PE showed significantly higher HtrA4 levels in serum compared with gestational age-matched controls. In cell models, high levels of HtrA4 disturbed endothelial cell tube formation and permeability in a dose-dependent manner, and this was linked to alterations in junctional proteins and microtubule organization. CONCLUSIONS HtrA4 represents a novel placenta-specific serine protease that is altered specifically in early-onset PE with potential causal roles in endothelial dysfunction and disease development.

[1]  T. Nero,et al.  Activity-Modulating Monoclonal Antibodies to the Human Serine Protease HtrA3 Provide Novel Insights into Regulating HtrA Proteolytic Activities , 2014, PloS one.

[2]  D. Charnock-Jones,et al.  Redefining preeclampsia using placenta-derived biomarkers. , 2013, Hypertension.

[3]  Ying Li,et al.  HtrA3 Is Downregulated in Cancer Cell Lines and Significantly Reduced in Primary Serous and Granulosa Cell Ovarian Tumors , 2013, Journal of Cancer.

[4]  H. Kurahashi,et al.  Upregulation of HtrA4 in the placentas of patients with severe pre-eclampsia. , 2012, Placenta.

[5]  Y. Li,et al.  HtrA3 as an Early Marker for Preeclampsia: Specific Monoclonal Antibodies and Sensitive High-Throughput Assays for Serum Screening , 2012, PloS one.

[6]  M. Cheong,et al.  High-Temperature Requirement Protein A4 (HtrA4) Suppresses the Fusogenic Activity of Syncytin-1 and Promotes Trophoblast Invasion , 2012, Molecular and Cellular Biology.

[7]  S. Tong,et al.  MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin , 2012, PloS one.

[8]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[9]  D. Schust,et al.  Preeclampsia: multiple approaches for a multifactorial disease , 2012, Disease Models & Mechanisms.

[10]  R. Levine,et al.  Preeclampsia, a Disease of the Maternal Endothelium: The Role of Antiangiogenic Factors and Implications for Later Cardiovascular Disease , 2011, Circulation.

[11]  Y. Endo,et al.  Decidual HtrA3 negatively regulates trophoblast invasion during human placentation. , 2011, Human reproduction.

[12]  R. Huber,et al.  HTRA proteases: regulated proteolysis in protein quality control , 2011, Nature Reviews Molecular Cell Biology.

[13]  E. Wallace,et al.  Placental HtrA3 is regulated by oxygen tension and serum levels are altered during early pregnancy in women destined to develop preeclampsia. , 2010, The Journal of clinical endocrinology and metabolism.

[14]  H. Kleinman,et al.  In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract , 2010, Nature Protocols.

[15]  J. Chien,et al.  High Temperature Requirement A3 (HtrA3) Promotes Etoposide- and Cisplatin-induced Cytotoxicity in Lung Cancer Cell Lines* , 2010, The Journal of Biological Chemistry.

[16]  R. Kalluri,et al.  The biology of preeclampsia. , 2009, Kidney international.

[17]  J. Chien,et al.  HtrA serine proteases as potential therapeutic targets in cancer. , 2009, Current cancer drug targets.

[18]  J. Chien,et al.  Serine Protease HtrA1 Associates with Microtubules and Inhibits Cell Migration , 2009, Molecular and Cellular Biology.

[19]  I. Sargent,et al.  Placental stress and pre-eclampsia: a revised view. , 2009, Placenta.

[20]  C. Hubel,et al.  The two stage model of preeclampsia: variations on the theme. , 2009, Placenta.

[21]  A. Rowan,et al.  Emerging roles of serine proteinases in tissue turnover in arthritis. , 2008, Arthritis and rheumatism.

[22]  T. Nikolskaya,et al.  A comprehensive functional analysis of tissue specificity of human gene expression , 2008, BMC Biology.

[23]  Y. Asmann,et al.  Elevated expression of serine protease HtrA1 in preeclampsia and its role in trophoblast cell migration and invasion. , 2008, American journal of obstetrics and gynecology.

[24]  H. Kurahashi,et al.  Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. , 2007, Placenta.

[25]  T. Libermann,et al.  Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.

[26]  Y. Li,et al.  Serine Peptidase HTRA3 Is Closely Associated with Human Placental Development and Is Elevated in Pregnancy Serum1 , 2006, Biology of reproduction.

[27]  I. Sargent,et al.  Latest Advances in Understanding Preeclampsia , 2005, Science.

[28]  Alfonso Baldi,et al.  Implications of the serine protease HtrA1 in amyloid precursor protein processing , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Lindheimer,et al.  World Health Organization Systematic Review of Screening Tests for Preeclampsia , 2004, Obstetrics and gynecology.

[30]  Asif Ahmed,et al.  Elevated Placental Soluble Vascular Endothelial Growth Factor Receptor-1 Inhibits Angiogenesis in Preeclampsia , 2004, Circulation research.

[31]  R. Romero,et al.  Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. , 2004, American journal of obstetrics and gynecology.

[32]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[33]  A. Baldi,et al.  Distribution of the Serine Protease HtrA1 in Normal Human Tissues , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[34]  J. Gamble,et al.  Supernatants from dengue virus type‐2 infected macrophages induce permeability changes in endothelial cell monolayers , 2003, Journal of medical virology.

[35]  L. Salamonsen,et al.  Identification and cloning of two isoforms of human high-temperature requirement factor A3 (HtrA3), characterization of its genomic structure and comparison of its tissue distribution with HtrA1 and HtrA2. , 2003, The Biochemical journal.

[36]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[37]  C. Southan,et al.  The HtrA family of proteases: implications for protein composition and cell fate. , 2002, Molecular cell.

[38]  D. Granger,et al.  Endothelial junctional protein redistribution and increased monolayer permeability in human umbilical vein endothelial cells isolated during preeclampsia. , 2002, American journal of obstetrics and gynecology.

[39]  J. Kooner,et al.  Association of maternal endothelial dysfunction with preeclampsia. , 2001, JAMA.

[40]  Jm Roberts,et al.  Pathogenesis and genetics of pre-eclampsia , 2001, The Lancet.

[41]  James J. Walker,et al.  Pre-eclampsia , 2000, The Lancet.

[42]  C. Southan,et al.  Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. , 2000, European journal of biochemistry.

[43]  D Bilder,et al.  Cooperative regulation of cell polarity and growth by Drosophila tumor suppressors. , 2000, Science.

[44]  C. Fusco,et al.  Characterization of a Novel Human Serine Protease That Has Extensive Homology to Bacterial Heat Shock Endoprotease HtrA and Is Regulated by Kidney Ischemia* , 2000, The Journal of Biological Chemistry.

[45]  D. Luk,et al.  Human HtrA, an Evolutionarily Conserved Serine Protease Identified as a Differentially Expressed Gene Product in Osteoarthritic Cartilage* , 1998, The Journal of Biological Chemistry.

[46]  M. O'Sullivan,et al.  Endothelial cell monolayers as a model system to investigate dengue shock syndrome. , 1998, Journal of virological methods.

[47]  M. Drab,et al.  Endothelial-cell permeability and protein kinase C in pre-eclampsia , 1998, The Lancet.

[48]  J. Zumbrunn,et al.  Primary structure of a putative serine protease specific for IGF‐binding proteins , 1996, FEBS letters.

[49]  M. Lampugnani,et al.  A novel endothelial-specific membrane protein is a marker of cell-cell contacts , 1992, The Journal of cell biology.

[50]  M. Brown,et al.  Capillary permeability and extracellular fluid volumes in pregnancy-induced hypertension. , 1989, Clinical science.

[51]  D. Powell,et al.  Barrier function of epithelia. , 1981, The American journal of physiology.